Jazz Pharmaceuticals

JAZZ

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Jazz Pharmaceuticals has been a target of short sellers for a while. The current short interest of 7.12% is roughly at the average of the last 12 months (7.56%).